Vascular Biogenics Stock Price, News & Analysis (NASDAQ:VBLT)

$6.30 -0.40 (-5.97 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$6.30
Today's Range$6.25 - $6.80
52-Week Range$3.90 - $9.05
Volume309,166 shs
Average Volume194,867 shs
Market Capitalization$199.15 million
P/E Ratio-7.97
Dividend YieldN/A
Beta-2.87

About Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics logoVascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.

Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VBLT
CUSIPN/A
Phone972-3634-6450

Debt

Debt-to-Equity RatioN/A
Current Ratio5.87%
Quick Ratio5.87%

Price-To-Earnings

Trailing P/E Ratio-7.97458260022025
Forward P/E Ratio-7.00
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.58 per share
Price / Book3.99

Profitability

Trailing EPS($0.79)
Net Income$-16,000,000.00
Net MarginsN/A
Return on Equity-58.36%
Return on Assets-51.16%

Miscellaneous

Employees34
Outstanding Shares29,730,000

Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd (NASDAQ:VBLT) issued its earnings results on Monday, August, 15th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.09. View Vascular Biogenics' Earnings History.

When will Vascular Biogenics make its next earnings announcement?

Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Monday, March, 26th 2018. View Earnings Estimates for Vascular Biogenics.

Where is Vascular Biogenics' stock going? Where will Vascular Biogenics' stock price be in 2018?

2 analysts have issued 12-month target prices for Vascular Biogenics' stock. Their forecasts range from $11.00 to $25.00. On average, they anticipate Vascular Biogenics' stock price to reach $18.00 in the next year. View Analyst Ratings for Vascular Biogenics.

Who are some of Vascular Biogenics' key competitors?

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the folowing people:

  • Bennett M. Shapiro, Chairman of the Board, Independent Director (Age 77)
  • Dror Harats, Chief Executive Officer, Director (Age 60)
  • Amos Ron, Chief Financial Officer & Company Secretary (Age 61)
  • Eyal Breitbart, Vice President - Research & Operations (Age 50)
  • Erez Feige, Vice President - Business Operations (Age 43)
  • Yael Cohen, Vice President - Clinical Development (Age 54)
  • Naamit Sher, Vice President - Drug Development & Regulatory Affairs (Age 62)
  • Ayelet Horn, General Counsel (Age 46)
  • Ruth Alon, Non-Executive Independent Director (Age 66)
  • Ron Cohen, Non-Executive Independent Director (Age 62)

Who owns Vascular Biogenics stock?

Vascular Biogenics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Macquarie Group Ltd. (0.68%), Raymond James & Associates (0.19%), ARK Investment Management LLC (0.14%), Alps Advisors Inc. (0.11%) and IFP Advisors Inc (0.07%). View Institutional Ownership Trends for Vascular Biogenics.

Who sold Vascular Biogenics stock? Who is selling Vascular Biogenics stock?

Vascular Biogenics' stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd.. View Insider Buying and Selling for Vascular Biogenics.

Who bought Vascular Biogenics stock? Who is buying Vascular Biogenics stock?

Vascular Biogenics' stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Alps Advisors Inc., Raymond James & Associates and IFP Advisors Inc. View Insider Buying and Selling for Vascular Biogenics.

How do I buy Vascular Biogenics stock?

Shares of Vascular Biogenics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vascular Biogenics' stock price today?

One share of Vascular Biogenics stock can currently be purchased for approximately $6.30.

How big of a company is Vascular Biogenics?

Vascular Biogenics has a market capitalization of $199.15 million. The biopharmaceutical company earns $-16,000,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Vascular Biogenics employs 34 workers across the globe.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 6 JONATHAN NETANYAHU ST., OR YEHUDA L3, 60376. The biopharmaceutical company can be reached via phone at 972-3634-6450 or via email at [email protected]


MarketBeat Community Rating for Vascular Biogenics (VBLT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  306
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vascular Biogenics (NASDAQ:VBLT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.00$15.67$16.00$14.75
Price Target Upside: 158.99% upside125.42% upside130.22% upside217.20% upside

Vascular Biogenics (NASDAQ:VBLT) Consensus Price Target History

Price Target History for Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics (NASDAQ:VBLT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017HC WainwrightReiterated RatingBuy$11.00N/AView Rating Details
11/6/2017Chardan CapitalBoost Price TargetBuy -> Buy$20.00 -> $25.00N/AView Rating Details
2/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$11.00N/AView Rating Details
12/1/2016Roth CapitalReiterated RatingBuy$17.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $8.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Vascular Biogenics (NASDAQ:VBLT) Earnings History and Estimates Chart

Earnings by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics (NASDAQ VBLT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018($0.05)N/AView Earnings Details
11/14/2017Q3 2017($0.20)($0.24)ViewN/AView Earnings Details
8/14/20176/30/2017($0.19)($0.18)ViewN/AView Earnings Details
5/15/20173/31/2017($0.17)($0.19)ViewN/AView Earnings Details
3/27/201712/31/2016($0.19)($0.18)ViewListenView Earnings Details
11/10/2016Q316($0.15)($0.12)ViewN/AView Earnings Details
8/15/2016Q2($0.23)($0.14)ViewListenView Earnings Details
5/13/2016Q1($0.21)($0.21)ViewListenView Earnings Details
3/29/2016Q4($0.32)($0.14)ViewListenView Earnings Details
11/12/2015Q315($0.19)($0.29)ViewListenView Earnings Details
8/13/2015Q215($0.19)($0.15)ViewListenView Earnings Details
5/12/2015Q115($0.19)($0.15)ViewListenView Earnings Details
3/25/2015($0.24)($0.25)ViewN/AView Earnings Details
11/14/2014($0.41)($4.16)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Vascular Biogenics (NASDAQ:VBLT) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.9 EPS
Next Year EPS Consensus Estimate: $-0.92 EPS

Dividends

Dividend History for Vascular Biogenics (NASDAQ:VBLT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vascular Biogenics (NASDAQ VBLT)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Vascular Biogenics (NASDAQ VBLT) News Headlines

Source:
DateHeadline
Vascular Biogenics (VBLT) Downgraded by Zacks Investment ResearchVascular Biogenics (VBLT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 23 at 6:08 PM
 Brokerages Anticipate Vascular Biogenics Ltd (VBLT) to Announce -$0.22 EPS Brokerages Anticipate Vascular Biogenics Ltd (VBLT) to Announce -$0.22 EPS
www.americanbankingnews.com - February 19 at 1:14 AM
VBL Therapeutics Receives Milestone Payment From NanoCarrier Under Licensing Agreement for VB-111 in JapanVBL Therapeutics Receives Milestone Payment From NanoCarrier Under Licensing Agreement for VB-111 in Japan
finance.yahoo.com - February 8 at 8:48 AM
Vascular Biogenics (VBLT) Lifted to "Hold" at Zacks Investment ResearchVascular Biogenics (VBLT) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 7 at 2:20 PM
Vascular Biogenics (VBLT) Rating Increased to Hold at ValuEngineVascular Biogenics (VBLT) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - February 4 at 9:02 AM
Vascular Biogenics (VBLT) Upgraded at Zacks Investment ResearchVascular Biogenics (VBLT) Upgraded at Zacks Investment Research
www.americanbankingnews.com - February 1 at 3:24 PM
Does Vascular Biogenics Ltd’s (NASDAQ:VBLT) CEO Pay Compared Well With Peers?Does Vascular Biogenics Ltd’s (NASDAQ:VBLT) CEO Pay Compared Well With Peers?
finance.yahoo.com - January 25 at 4:18 PM
Zacks Investment Research Lowers Vascular Biogenics (VBLT) to SellZacks Investment Research Lowers Vascular Biogenics (VBLT) to Sell
www.americanbankingnews.com - January 25 at 3:34 PM
Vascular Biogenics (VBLT) Lifted to Hold at Zacks Investment ResearchVascular Biogenics (VBLT) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - January 6 at 10:20 AM
Vascular Biogenics Ltd (NASDAQ:VBLT): Is Healthcare An Attractive Sector Play?Vascular Biogenics Ltd (NASDAQ:VBLT): Is Healthcare An Attractive Sector Play?
finance.yahoo.com - January 5 at 10:46 AM
Vascular Biogenics Target of Unusually Large Options Trading (VBLT)Vascular Biogenics Target of Unusually Large Options Trading (VBLT)
www.americanbankingnews.com - January 5 at 2:10 AM
Should you invest in Advanced Micro Devices, International Business Machines, Intel, Target or Vascular Biogenics?Should you invest in Advanced Micro Devices, International Business Machines, Intel, Target or Vascular Biogenics?
www.prnewswire.com - January 3 at 9:47 AM
VBL Therapeutics Announces the Appointments of Susan Kelley and David Hastings to Its Board of DirectorsVBL Therapeutics Announces the Appointments of Susan Kelley and David Hastings to Its Board of Directors
finance.yahoo.com - January 3 at 9:47 AM
Implied Volatility Surging for Vascular Biogenics (VBLT) Stock OptionsImplied Volatility Surging for Vascular Biogenics (VBLT) Stock Options
finance.yahoo.com - January 2 at 10:23 AM
Zacks: Analysts Expect Vascular Biogenics Ltd. (VBLT) to Post -$0.22 EPSZacks: Analysts Expect Vascular Biogenics Ltd. (VBLT) to Post -$0.22 EPS
www.americanbankingnews.com - December 30 at 7:46 AM
VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Collaboration with the GOG Foundation, Inc.VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Collaboration with the GOG Foundation, Inc.
finance.yahoo.com - December 27 at 1:14 PM
What Falling Estimates & Price Mean for Vascular Biogenics (VBLT) - NasdaqWhat Falling Estimates & Price Mean for Vascular Biogenics (VBLT) - Nasdaq
www.nasdaq.com - December 18 at 4:22 PM
New Biomarker Data Supports Direct Link between VB-111’s Dual Mechanism of Action and its Clinical Effect on Overall Survival and Progression Free Survival in Recurrent Glioblastoma Multiforme PatientsNew Biomarker Data Supports Direct Link between VB-111’s Dual Mechanism of Action and its Clinical Effect on Overall Survival and Progression Free Survival in Recurrent Glioblastoma Multiforme Patients
finance.yahoo.com - December 18 at 11:01 AM
What Falling Estimates & Price Mean for Vascular Biogenics (VBLT)What Falling Estimates & Price Mean for Vascular Biogenics (VBLT)
finance.yahoo.com - December 18 at 11:01 AM
Vascular Biogenics Ltd. (VBLT) Expected to Post Earnings of -$0.20 Per ShareVascular Biogenics Ltd. (VBLT) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - December 13 at 5:12 AM
Vascular Biogenics Ltd. (VBLT) Receives Consensus Rating of "Hold" from BrokeragesVascular Biogenics Ltd. (VBLT) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 30 at 4:04 PM
Zacks: Analysts Expect Vascular Biogenics Ltd. (VBLT) to Announce -$0.20 EPSZacks: Analysts Expect Vascular Biogenics Ltd. (VBLT) to Announce -$0.20 EPS
www.americanbankingnews.com - November 25 at 9:26 AM
Vascular Biogenics Ltd. (VBLT) Downgraded by Zacks Investment ResearchVascular Biogenics Ltd. (VBLT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 24 at 6:32 AM
Vascular Biogenics Ltd. (VBLT) Given "Buy" Rating at HC WainwrightVascular Biogenics Ltd. (VBLT) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - November 21 at 4:41 PM
Why Vascular Biogenics Ltd. Is Tanking Today - Motley FoolWhy Vascular Biogenics Ltd. Is Tanking Today - Motley Fool
www.fool.com - November 18 at 9:59 AM
Why Vascular Biogenics Ltd. Is Tanking TodayWhy Vascular Biogenics Ltd. Is Tanking Today
www.fool.com - November 17 at 12:56 PM
Vascular Biogenics Ltd (VBLT) PT Raised to $10 at JMP Securities - StreetInsider.comVascular Biogenics Ltd (VBLT) PT Raised to $10 at JMP Securities - StreetInsider.com
www.streetinsider.com - November 16 at 5:24 AM
Vascular Biogenics Ltd. to Host Earnings CallVascular Biogenics Ltd. to Host Earnings Call
finance.yahoo.com - November 16 at 5:24 AM
VBL Therapeutics Announces Third Quarter 2017 Financial ResultsVBL Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 16 at 5:24 AM
Vascular Biogenics reports 3Q lossVascular Biogenics reports 3Q loss
finance.yahoo.com - November 16 at 5:24 AM
Edited Transcript of VBLT earnings conference call or presentation 14-Nov-17 1:30pm GMTEdited Transcript of VBLT earnings conference call or presentation 14-Nov-17 1:30pm GMT
finance.yahoo.com - November 16 at 5:24 AM
Who Are The Major Shareholders Of Vascular Biogenics Ltd (VBLT)?Who Are The Major Shareholders Of Vascular Biogenics Ltd (VBLT)?
finance.yahoo.com - November 13 at 8:23 PM
VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18
finance.yahoo.com - November 9 at 9:23 AM
BRIEF-VBL Therapeutics and Nanocarrier sign exclusive agreement for VB-111 in JapanBRIEF-VBL Therapeutics and Nanocarrier sign exclusive agreement for VB-111 in Japan
www.reuters.com - November 7 at 11:26 PM
BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in JapanBRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan
www.businessinsider.com - November 7 at 11:26 PM
Form 6-K Vascular Biogenics Ltd. For: Nov 06 - StreetInsider.comForm 6-K Vascular Biogenics Ltd. For: Nov 06 - StreetInsider.com
www.streetinsider.com - November 7 at 1:00 PM
Vascular Biogenics Ltd (VBLT) PT Raised to $25 at Chardan Capital Markets - StreetInsider.comVascular Biogenics Ltd (VBLT) PT Raised to $25 at Chardan Capital Markets - StreetInsider.com
www.streetinsider.com - November 7 at 1:00 PM
VBL Therapeutics to Report Third Quarter 2017 Results on November 14VBL Therapeutics to Report Third Quarter 2017 Results on November 14
finance.yahoo.com - November 7 at 12:59 PM
Vascular Biogenics Ltd. (VBLT) Expected to Announce Earnings of -$0.18 Per ShareVascular Biogenics Ltd. (VBLT) Expected to Announce Earnings of -$0.18 Per Share
www.americanbankingnews.com - November 6 at 1:20 PM
Vascular Biogenics Ltd. (VBLT) Given New $25.00 Price Target at Chardan CapitalVascular Biogenics Ltd. (VBLT) Given New $25.00 Price Target at Chardan Capital
www.americanbankingnews.com - November 6 at 11:38 AM
VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan - GlobeNewswire (press release)VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan - GlobeNewswire (press release)
globenewswire.com - November 6 at 8:48 AM
VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in JapanVBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan
finance.yahoo.com - November 6 at 8:48 AM
Vascular Biogenics Ltd. (VBLT) Given Consensus Recommendation of "Buy" by BrokeragesVascular Biogenics Ltd. (VBLT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 5 at 4:02 PM
Critical Survey: Vascular Biogenics (VBLT) vs. Gemphire Therapeutics (GEMP)Critical Survey: Vascular Biogenics (VBLT) vs. Gemphire Therapeutics (GEMP)
www.americanbankingnews.com - November 4 at 11:40 PM
Vascular Biogenics Ltd. (VBLT) to Release Earnings on WednesdayVascular Biogenics Ltd. (VBLT) to Release Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
Vascular Biogenics Stock May Shoot Up On The Back Of Upcoming Catalysts - Seeking AlphaVascular Biogenics Stock May Shoot Up On The Back Of Upcoming Catalysts - Seeking Alpha
seekingalpha.com - October 31 at 11:41 AM
VBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company HeadquartersVBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company Headquarters
finance.yahoo.com - October 23 at 8:47 AM
VBL Therapeutics Announces Orphan Drug Designation for VB-111 in EuropeVBL Therapeutics Announces Orphan Drug Designation for VB-111 in Europe
finance.yahoo.com - October 20 at 9:47 AM
Vascular Biogenics Ltd. (VBLT) Receives Average Rating of "Hold" from BrokeragesVascular Biogenics Ltd. (VBLT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 11 at 4:42 PM
VBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBMVBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBM
finance.yahoo.com - October 3 at 2:26 PM

SEC Filings

Vascular Biogenics (NASDAQ:VBLT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vascular Biogenics (NASDAQ:VBLT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vascular Biogenics (NASDAQ VBLT) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.